Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol 2017; 23(20): 3690-3701 [PMID: 28611522 DOI: 10.3748/wjg.v23.i20.3690]
Corresponding Author of This Article
Daniele Nicolini, MD, PhD, Division of Hepatobiliary and Transplant Surgery, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, via Tronto n°10/a, 60126 Ancona, Italy. daniele.nicolini@ospedaliriuniti.marche.it
Research Domain of This Article
Transplantation
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Characteristics of TACE and time-intervals between procedures
Number of treatments [median (IQRs)]
2 (1-2)
Repeated TACE
37 (52.9)
Type of TACE (DEB/conventional)
54 (77.1)/16 (22.9)
Interval of last imaging-LT (mo) [median (IQRs)]
1.4 (0.7-2.7)
Interval of last TACE-LT (mo) [median (IQRs)]
3.9 (2.1-7.4)
Interval of first TACE-LT (mo) [median (IQRs)]
6.9 (3.7-11.0)
Table 2 Radiological and laboratory characteristics of the study population after transarterial chemoembolization procedures and tumour histopathological data n (%)
Variable
All treated patients (n = 70)
Pre-LT radiological evaluation
mRECIST overall response
Complete/partial response
24 (34.3)/26 (37.1)
Stable/progressive disease
10 (14.3)/10 (14.3)
EASL overall response
Complete/partial response
24 (34.3/25 (35.7)
Stable/progressive disease
11 (15.7)/10 (14.3)
Number of enhancing nodules [median (IQRs)]
1 (0.0-2.0)
None/single/multiple
24 (34.3)/22 (31.4)/24 (34.3)
Sum of enhancing diameters (cm) [median (IQRs)]
1.4 (0.0-3.3)
Sum of enhancing diameters > 5 cm
8 (11.4)
Diameter of the largest enhancing nodule (cm) [median (IQRs)]
% of necrosis on cumulative tumour area (100/99-50/< 50)
14 (20.0)/28 (40.0)/28 (40.0)
Table 3 Correlation analysis between histological necrosis and radiological response according to modified Response Evaluation Criteria in Solid Tumours and European Association for the Study of the Liver criteria n (%)
Table 4 Univariate and multivariate analysis of the preoperative risk factors related to tumour recurrence
Risk factors
Univariate analysis
Multivariate analysis
3-yr RFS rate (%)
HR (95%CI)
Log-rank P value
Exp(b) (95%CI)
P value
Pre-TACE radiological and laboratory evaluation
Exceeding Milan criteria
77.7 vs 91.2
3.41 (0.78-14.92)
0.074
Exceeding UCSF criteria
60.6 vs 92.8
5.06 (0.78-32.74)
0.011
4.69 (1.14-19.30)
0.033
Multiple nodules
77.2 vs 93.4
4.33 (1.06-17.72)
0.049
1.77 (0.27-11.48)
0.550
AFP > 400 ng/mL
80.0 vs 85.3
1.96 (0.13-30.81)
0.520
NLR > 4
100 vs 80.4
NA
0.185
PLR > 150
50.0 vs 88.6
5.98 (0.06-573.48)
0.059
Pre-LT radiological and laboratory evaluation
mRECIST non response
71.2 vs 94.3
6.96 (1.54-31.50)
0.006
9.19 (1.65-51.30)
0.012
EASL non response
76.8 vs 91.6
3.67 (0.82-16.34)
0.056
AFP > 400 ng/mL
83.3 vs 89.0
4.74 (0.29-77.77)
0.034
1.43 (0.23-9.10)
0.703
AFP increase > 15 ng/mL per month
41.7 vs 87.7
3.89 (0.30-50.72)
0.072
NLR > 4
80.8 vs 87.9
1.54 (0.25-9.41)
0.594
NLR increase > 0.24/mo
83.3 vs 100
NA
0.114
PLR > 150
50.0 vs 89.1
5.32 (0.28-101.01)
0.022
5.95 (1.04-33.95)
0.046
PLR increase > 3.04
80.8 vs 88.7
1.48 (0.24-9.04)
0.636
Citation: Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol 2017; 23(20): 3690-3701